Foraging for the Optimal Dressing Scaffold to Carry Adipose-Derived Stromal/Progenitor Cells for Cell Therapy

Chia-Chieh Wu1,2,3,4*, Ying-Cheh Chen5*, Yi-Chia Wu1,6,7, Shu-Hung Huang1,6,7, Yur-Ren Kuo1,6,7, and Su-Shin Lee1,5,6,7

Abstract
In our daily plastic surgery practice, we have seen many chronic wounds that need new biotechnology to help and improve wound healing. Stem cells play a crucial role in regenerative medicine. Many pre-clinical researches had reported the beneficial paracrine effects of stem cell therapy for chronic wounds. Cell-friendly scaffolds may provide the protection and three-dimensional space required for adherence of stem cells, thus allowing these stem cells to proliferate and differentiate for treatment purpose. A successful scaffold may enhance the effects of stem cell therapy. In this presented series, the authors attempted to identify the most suitable scaffolds from several commercially available wound dressings that could sustain adipose-derived stromal/progenitor cells (ADSCs) survival. Therefore, we isolated ADSCs containing the green fluorescent protein (GFP) from GFP transgenic rats. The GFP (+) ADSCs and their progenies could be easily observed using a fluorescence microscope. Moreover, we analyzed the cytokines secreted in condition medium (CM) to understand the activities of ADSCs in various dressings. Our results showed that the foam dressings, hydrofiber, chitosan, and alginate plus carboxymethylcellulose were identified as the most suitable dressing materials. Higher concentrations of transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF) were observed 48 h after loading them with GFP (+) ADSCs. Therefore, multiple topical cell therapy using ADSCs can be performed by applying suitable dressing scaffolds without repeated needle injections to deliver the stem cells into the wound bed. Based on their fluorescence property, the GFP (+) ADSCs can also possibly be used for testing biocompatibility of medical materials in the future.

Keywords
ADSCs, scaffold, commercial dressing, condition medium

Introduction
The current management of chronic wounds includes wound dressing, bedside debridement, infection control, moisture balance, and vascular assessment1,2. Originally, wound dressings were used to protect the wound base. With the advances made in understanding the wound-healing process, several wound dressings have been designed to maintain an optimal amount of moisture and provide an ideal environment for epithelial migration1,2. Numerous types of commercially available wound dressings promote wound healing. Moreover, the selection of dressings is usually based on a physician’s personal experience, availability, wound condition, cost, and patient’s preference1.

Zuk et al.4 first reported the use of adipose-derived stromal/progenitor cells (ADSCs) to improve wound healing with promising results5-8. ADSCs have the capacity of prolonged or unlimited self-renewal and ability to differentiate into multiple lineages9. Furthermore, the paracrine effects of the ADSCs regulate the levels of cytokines around the wound site to enhance wound healing10,11. In the clinical setting of...
cell therapy, simultaneously maintaining the contact between ADSCs and the wound bed and keeping them viable are challenges that require to be solved. However, this involves repeated local injections, which makes using ADSCs in clinical practice difficult. Therefore, ADSC scaffolds have been developed as a reasonable option for chronic wound treatment. In our earlier studies, we successfully isolated ADSCs from the inguinal fatty tissue of Wistar rats. We reported the use of ADSCs to screen possible scaffold candidates from commercially available materials used during routine surgery. In this study, we explored possible wound dressing materials that can be used as scaffolds to carry ADSCs. We harvested the inguinal fatty tissue from a green fluorescent protein (GFP) transgenic SD rat and cultured ADSCs. These GFP (+) ADSCs can be traced repeatedly under a fluorescence microscope in every generation.

We gathered 12 types of commercially available wound dressing materials in the clinics. The optimal scaffold had to demonstrate a high biocompatibility and be able to enhance the survival of ADSCs. We wanted to identify ADSC-friendly dressings that could serve as ADSC carriers for chronic wound cell therapy in the future.

Materials and Methods

Harvesting Adipose Tissue From GFP Transgenic Rat and Cultivating ADSCs

An SD-Tg (UBC-emGFP) 18Narl transgenic rat was purchased from the Genetic Engineering Murine Model Services, National Laboratory Animal Center (GEMMS-NLAC) in Taipei, Taiwan. The preparation procedures have been described by our colleagues previously. Briefly, this GFP (+) SD rat was anesthetized using an intraperitoneal injection with Zoletil 50 (50 mg/kg, Virbac Taiwan Co, Ltd, Taipei, Taiwan). Approximately 15 g subcutaneous tissue was excised from the inguinal area bilaterally. The tissue was rinsed using n-phosphate-buffered saline (n-PBS) to clean the erythrocytes. After centrifugation at 1,500 × g for 5 min, the tissue was moved to a 10-cm dish and washed. After cutting the fat tissue into small pieces, collagenase (1.5 mg/ml) was added. Then, the dish was incubated in the Dulbecco’s modified Eagle medium (DMEM) at 37°C for 20–30 min. Next, the tissues were centrifuged at 1,200× g for 5 min to remove the collagenase solution. These pellets were washed and incubated at 37°C in DMEM with 10% fetal bovine serum (FBS), 1% penicillin, 2 mM NAC, and 0.2 mM ascorbic 2-phosphate in a 5% CO2 incubator. These cells were then shifted to the keratinocyte-SFM medium the next day. The medium was changed every other day until confluence was achieved. These primary cultured cells were then collected for use by trypsinization and maintained for subculturing or stored in liquid nitrogen.

Adipogenesis Differentiation of ADSCs

Following the induction procedure reported by Lin et al., these primary cultured cells were treated by adipogenesis supplantations in DMEM. Oil red stain was used to monitor their successful differentiation into adipocytes.

Fluorescence-Activated Cell Sorting Analysis of ADSCs

According to the Concise Review of ADSCs written by Schaffler and Buchler, the surface markers CD90.1, CD44H, CD11b/c, CD45, and CD79α were examined. The ADSCs within the third passage were harvested and fixed in neutralized 2% paraformaldehyde solution for 30 min. These fixed cells were washed twice with PBS and incubated with antibodies against CD90.1, CD44H, CD11b/c, CD45, and CD79α for 30 min. The surface antigens of these cells were identified using flow cytometric analysis.

Seeding the ADSCs Into 12 Types of Wound Dressing Scaffolds and Synthesis of the Condition Medium

The following 12 types of wound dressings were collected in plastic surgery clinics to test their biocompatibility: Acticoat® Dressing (polyethylene mesh), AnsCare® ChitoClot Gauze (chitosan), Aquacel® foam (hydrofiber + foam), Aquacel® (hydrofiber), Atrauman-Ag® (hydrofiber), Atrauman-Ag® (polyamide mesh), Biatian® Alginate Dressing [alginate + carboxymethylcellulose (CMC)], Collawound® matrix wound dressing (collagen Sponge), Mepilex Ag® (foam), PELNAC® (collagen sponge), SeaSorb Ag® (alginate + CMC), and Versiva® XC (foam). A 5-mm punch was used to cut the dressing materials and placed in a 96-well nonadhesive tissue culture plate. Keratinocyte-SFM (serum-free medium) was used to moisten these wound dressings; then, 3 × 10^5 GFP (+) ADSCs were loaded on each dressing material (n = 5) (Figs. 4 and 5). This culture plate was incubated at 37°C for 48 h and then the condition medium (CM) was collected for enzyme-linked immunosorbent assay (ELISA) examination to determine the concentration of three different cytokines.

ELISA for Condition Medium

Three types of cytokines namely platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), and vascular endothelial growth factor (VEGF) were selected, as they were involved in wound healing. DuoSet ELISA development kits (R&D Systems, Minneapolis, MN, USA) were purchased. The assay was performed according to the manufacturer’s instructions. PDGF, TGF-β, and VEGF
were monitored for 48 h after loading ADSCs. The TGF-β kit required a serum-free cell culture condition.

**Statistical Analysis**

All data values are presented as the mean values with standard deviations. Five independent experiments were performed for each wound dressing. Data were analyzed using Tukey’s test. Statistical significance was assumed at a $P$ value of $<0.05$.

**Results**

**Characterization and Verification of GFP (+) ADSCs**

The cell morphology of the primary cultured cells from the SD-Tg(UBC-emGFP) 18Narl rat was assessed under a fluorescence microscope (Fig. 1). The results of adipogenesis differentiation with/without oil red stain are illustrated in Fig. 2. The flow cytometry analysis of GFP-ADSCs surface antigen, CD90.1, and CD44H were positive, whereas that of CD11b/c, CD45, and CD79α were negative. The isotype control was also negative (Fig. 3). These data proved that the primary cultured GFP (+) cells had the characteristics of ADSCs. The cumulative population doubling level (CPDL) was performed. At 24, 48, 72, 96, and 120 h, the level of proliferation are 140%, 320%, 660%, 1,450%, and 2,330%, respectively (supporting data).

**Images of GFP (+) ADSCs Incubated in the 12 Dressing Materials at 48 h**

The fluorescence microscope was used to assess these dressing materials. The GFP (+) ADSCs could be seen in some of the images. In some dressing, the ADSCs gathered together to become “spheres” (Figs. 4 and 5). However, these images did not represent the entire amount of ADSCs on the dressing materials. They provided information only on the qualitative analysis.
Cell Transplantation

Cytokine Concentration in the CM

ADSCs secrete various cytokines. To understand the quantities of ADSCs and their responses when implanted on various scaffolds, the culture media that were used for these GFP (+) ADSCs in daily care were collected. These media were checked for PDGF-αβ, TGF-β1, and VEGF. However, no difference was noted in the concentrations of PDGF-αβ among these CMs (Table 1). Significantly high concentrations of TGF-β1 and VEGF were noted in the foam dressing, chitosan dressing, hydrofiber, and alginate plus CMC groups (Tables 2 and 3).

Discussion

The wound-healing process is highly regulated by secretion of various growth factors, cytokines, and chemokines.

Chronic wounds require an extended healing period because their endogenous healing mechanisms are disrupted. With technological advancements, administration of exogenous growth factors has shown promise in stimulating chronic wound healing. However, the cost of recombinant human growth factors is high, and proper conservation to maintain their bioactivities is an uncertain issue. Cell therapy has recently gained attention because it provides new hope for patients who have not experienced successful wound healing by conventional treatments. Different cells (fibroblasts, keratinocytes, platelets, ADSCs) have been used to convert the wound bed into an environment where maximum wound healing can be achieved.

ADSCs were evaluated for regenerative application because these cells are easy to isolate, relatively abundant, and multipotent. The stem cells’ therapeutic potential is largely due to their capability to secrete pro-regenerative factors.
Figure 3. Flow cytometry analysis of green fluorescent protein (GFP)-adipose-derived stromal/progenitor cell (ADSC) surface antigens. CD90.1 and CD44H were positive, whereas CD11b/c, CD45, and CD79α were negative, and the isotype control was also negative.

Figure 4. (A) Green fluorescent protein (GFP) (+) adipose-derived stromal/progenitor cells (ADSCs) incubated in Aquacel foam 48 h, bright field, magnification 100×, (B) fluorescent images of the same view of (A), ADSC spheres noted; (C) GFP (+) ADSCs incubated in Aquacel hydrofiber 48 h, bright field, magnification 100×, and (D) fluorescent images of the same view of (C), ADSC spheres noted.
cytokines, causing them to be an attractive choice for the
treatment of chronic wounds\textsuperscript{16}. ADSCs can promote wound
healing and trigger neovascularization through their ability
to differentiate endothelial cells and release VEGF\textsuperscript{20}. The
ADSCs could differentiate within the epithelium or secrete
several types of cytokines (paracrine effect) that stimulated

Table 1. The Level of PDGF-αβ Secreted From GFP (+) ADSC in Different Medical Materials.

| PDGF-αβ (pg/ml) | Mean ± SD | Range |
|-----------------|-----------|-------|
| Control K-medium only | 2.1 ± 1.3 | 0.08–3.34 |
| Ag (−) Versiva XC (foam) | 5.0 ± 0.7 | 4.03–5.66 |
| PELNAC (collagen sponge) | 4.6 ± 1.7 | 2.17–5.90 |
| Aquacel foam (hydrofiber + foam) | 4.3 ± 1.6 | 2.17–6.13 |
| Collawound (collagen Sponge) | 4.3 ± 1.0 | 2.87–5.20 |
| Biatian Alginate (alginate + CMC) | 3.9 ± 1.5 | 2.41–6.13 |
| Aquacel (hydrofiber) | 3.2 ± 0.9 | 2.17–4.27 |
| AnsCare (chitosan) | 3.0 ± 1.3 | 1.71–4.97 |
| Ag (+) Seasorb Ag (alginate + CMC) | 5.3 ± 1.6 | 4.03–7.52 |
| Mepilex Ag (foam) | 4.0 ± 1.9 | 2.17–6.59 |
| Atrauman Ag (polyamide mesh) | 3.3 ± 1.7 | 1.24–5.20 |
| Aquacel Ag (hydrofiber) | 3.1 ± 1.9 | 1.01–5.43 |
| Acticoat (polyethylene mesh) | 3.0 ± 0.9 | 1.71–4.03 |

Groups not sharing a same letter (\textsuperscript{a, b, c, d}) are significantly different and group sharing (*) are significantly different by Tukey’s test ($P < 0.05$) ($n = 5$).

ADSC: adipose-derived stromal/progenitor cell; CMC: carboxymethylcellulose; GFP: green fluorescent protein; PDGF: platelet-derived growth factor.
Tremolada et al.\textsuperscript{22} reported a novel Lipogems® technology which helped to enhance the healing of lower leg chronic ulceration, especially in diabetic patients. The exosome content has been demonstrated to be significantly greater in fat tissue processed with Lipogems® than with the enzymatic method. The Lipogems® system yields a microfragmented autologous adipose tissue that acts as a large-scale tool to supply damaged tissues with a regenerative environment in a one-step intervention\textsuperscript{22}. This method can activate the natural healing process without using enzymes, additives, or separation centrifugation and relying instead on mild mechanical forces\textsuperscript{23}. ADSCs are extremely promising as an alternative tool for the regenerative strategy for wound therapy\textsuperscript{16}.

Kallmeyer et al.\textsuperscript{24} reported local injections of ADSCs for rat wound model cell therapy. Their ADSCs were transduced to express both GFP and firefly luciferase to enable tracking by immune-histological analysis and bioluminescence imaging. They found that these local injected ADSCs could become distributed within the wound bed in 24 h. And these ADSCs were strongly detectable up to 7 days. In our earlier animal studies\textsuperscript{8}, the authors had reported ADSC injections for the animal chronic wound model cell therapy. However, merely applying the ADSCs over the wound surface would be less invasive. Topical coverage with ADSCs might make it easier for the institutional review board to approve our human clinical trial in the future. Therefore, identification of suitable scaffolds that could carry as many ADSCs as possible should be explored in future research.

Clinical physicians are not specialized in chemical synthesis and are unable to create new scaffold materials. Commercially available dressings might reduce the concerns...
of biotoxicity from new chemical synthetic materials. Hence, we tested several commercially available wound dressings to evaluate their potential as ADSC carrier scaffolds and examine their biocompatibility.

In this present series, we harvested the adipose tissue from the GFP (+) transgenic SD rat to isolate GFP (+) ADSCs. Moreover, the surface antigens of our primary cultured cell lines were CD90.1(+) and CD44H(+), whereas CD11b/c, CD45, and CD79a were all negative as observed using flow cytometry analysis15. We have proven that our primary culture cell lines possess the characteristics of stem cells10,13. GFP (+) ADSCs were used to serve as a biocompatibility testing tool.

In this study, we identified the most cell-friendly commercial wound dressings and sought potential scaffold candidates that could serve as ADSC carriers during cell therapy for difficult wounds. Because each generation of GFP (+) ADSCs could be observed under a fluorescence microscope, we could trace the positions of GFP (+) ADSCs repeatedly. However, these wound dressings were not transparent. We also detected fluorescence in some of the dressing materials under the fluorescence microscope. Fluorescence microscope observations could be considered only as a “qualitative analysis.” We were unable to identify which dressing material was superior using only fluorescence microscope findings. The ADSCs that survived within the scaffolds would be able to secrete various cytokines. The amount of cytokine secretion is proportional to the survived number of ADSCs. Therefore, the cytokine levels in the CM were studied.

The ADSCs can emanate a variety of cytokines, and several studies have reported on the ADSC-CM12,25–27. The ADSCs promote proliferation of dermal fibroblasts by using not only cell-to-cell contact but also paracrine cytokines29. In this series, we collected and analyzed the CMs from $3 \times 10^5$ GFP (+) ADSCs in different commercially available dressing materials. We measured the concentrations of PDGF, TGF-β, and VEGF by using the ELISA technique because these three cytokines were crucial growth factors that might improve wound healing. From the viewpoint of cell therapy, a better scaffold should possess a higher concentration of these cytokines in their CMs. In clinical practice, the chronic wounds shall be inspected and changed dressing daily or every other day to prevent wound infection. The old dressing will be removed and discarded. A new dressing will be applied to the wound. So, in the clinical cell therapy “ADSCs carrying dressing” may cover the wound for 24 to 48 h. Then, another new ADSCs carrying dressing will replace the old one. Therefore, in this study, we evaluate the cytokine levels from the 48 h of ADSC dressings’ CM.

Our results revealed no significant differences in PDGF levels (Table 1). However, obvious variations were noted in the concentrations of TGF-β1 and VEGF in different dressing materials (Tables 2 and 3). In general, dressing materials with nanosilver particles were less cell-friendly in comparison with dressings without these particles. Moreover, the dressings with high concentrations of TGF-β1 (>30 pg/ml) were Versiva® XC (foam), AquaCel® foam (hydrofiber + foam), and AnsCare® (chitosan). Also, Versiva® XC (foam), AquaCel® foam (hydrofiber + foam), AquaCel® (hydrofiber), AnsCare® (chitosan), and SeaSorb Ag® (alginate + CMC) demonstrated high concentrations of VEGF (>100 pg/ml).

**Limitation**

Our study has several limitations. First, the GFP (+) cells can only be seen in the transparent scaffold. The non-transparency and some unknown fluorescent material in the dressings make our observation difficult. Second, the ADSCs may survive on the dressing longer than 48 h. However, this study design did not investigate the pattern or growth of ADSCs on the dressing longer than 48 h. Further research may be needed to study the longevity of ADSCs on these dressing. Third, in clinical situation, some ADSCs may translocate to the wound bed. This study did not provide information about this issue. Further analyses and investigations are suggested.

**Conclusion**

In summary, we successfully isolated GFP (+) ADSCs from the GFP (+) transgenic SD rat. The adipogenesis differentiation and sorting of surface antigen cells proved that these primary cultured cell lines had the characteristics of stem cells. The GFP (+) ADSCs were then used to test 12 types of commercially available wound dressings. We identified three types of dressings with TGF-β1 concentrations of >30 pg/ml in the CM and five types of dressings with VEGF concentrations of >100 pg/ml in the CM. VEGF and TGF-β1 are growth factors vital for wound healing. This study demonstrated that we can select appropriate scaffold dressings for autologous ADSCs seeding to perform cell therapy in human patients with chronic wounds. Moreover, based on their fluorescence property, the GFP (+) ADSCs can possibly be used for testing biocompatibility of medical materials in the future.

**Acknowledgments**

The authors would like to thank the Genetic Engineering Murine Model Services (GEMMS), National Core Facility Program for Biotechnology, Ministry of Science and Technology for providing the SD-Tg (UBC-emGFP) 18Narl transgenic rat used in this study.

**Ethical Approval**

This study had been approved by the Institutional Animal Care and Use Committee (IACUC) of Kaohsiung Medical University, Kaohsiung, Taiwan.

**Statement of Human and Animal Rights**

All of the experimental procedures involving animals were conducted in accordance with the Institutional Animal Care and Use...
Committee guidelines of Kaohsiung Medical University, Kaohsiung, Taiwan.

Statement of Informed Consent
There are no human subjects in this article and informed consent is not applicable.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a grant from Changhua Christian Hospital-Kaohsiung Medical University Research Funding (10-CCH-KMU-011 and KMUH101-1R22) and Kaohsiung Municipal Siaogang Hospital (KMSH P-110-12 and KMSH H-109-06).

Supplemental Material
Supplemental material for this article is available online.

References
1. Dabiri G, Damstetter E, Phillips T. Choosing a wound dressing based on common wound characteristics. Adv Wound Care (New Rochelle). 2016;5(1): 32–41.
2. Bowers S, Franco E. Chronic wounds: evaluation and Management. Am Fam Physician. 2020;101(3): 159–66.
3. Paddle-Ledinke JF, Nasa Z, Cleland HJ. Effect of different wound dressings on cell viability and proliferation. Plast Reconstr Surg. 2006;117(7Suppl): 110S–118S; discussion 119S–120S.
4. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang J/L, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13(12): 4279–95.
5. Veronesi F, Maglio M, Tschon M, Aldini NN, Fini M. Adipose-derived mesenchymal stem cells for cartilage tissue engineering: state-of-the-art in in vivo studies. J Biomed Mater Res A. 2014;102(7): 2448–66.
6. Verité S, Andre W, Aouassar N, Poirel HA, Lafaosse A, Docquier PL, Dufranne D. Human adipose-derived mesenchymal stem cells in cell therapy: safety and feasibility in different “Hospital Exemption” Clinical Applications. PLOS ONE. 2015;10(10): e0139566.
7. Xi J, Yan X, Zhou J, Yue W, Pei X. Mesenchymal stem cells in tissue repair and regeneration: process and future. Burns Trauma. 2013;1(1): 13–20.
8. Chang YW, Wu YC, Huang SH, Wang HD, Kuo YR, Lee SS. Autologous and not allogeneic adipose-derived stem cells improve acute burn wound healing. PLOS ONE. 2018;13(5): e0197744.
9. Huayllani MT, Sarabia-Estrada R, Restrepo DJ, Boczar D, Sisti A, Nguyen JH, Rinker BD, Moran SL, Quinones-Hinojosa A, Forte AJ. Adipose-derived stem cells in wound healing of full-thickness skin defects: a review of the literature. J Plast Surg Hand Surg. 2020;54(5): 263–79.
10. Sheen Y-T, Lin T-M, Chang K-P, Lai C-S, Lin S-D, Lee S-S. Commercially available materials as scaffold candidates for adipose-derived stromal/progenitor cell tissue engineering. Formosan J Surg. 2014;47(1): 1–10.
11. Boateng J, Catanzano O. Advanced therapeutic dressings for effective wound healing—a review. J Pharm Sci. 2015;104(11): 3653–80.
12. Cai Y, Li J, Jia C, He Y, Deng C. Therapeutic applications of adipose cell-free derivatives: a review. Stem Cell Res Ther. 2020;11(1): 312.
13. Lin TM, Chang HW, Wang KH, Kao AP, Chang CC, Wen CH, Lai CS, Lin SD. Isolation and identification of mesenchymal stem cells from human lipoma tissue. Biochem Biophys Res Commun. 2007;361(4): 883–89.
14. Lee SS, Wu YC, Huang SH, Chen YC, Srinivasan P, Hsieh DJ, Yeh YC, Lai YP, Lin YN. A novel 3D histotopic cartilage construct engineered by supercritical carbon dioxide decellularized porcine nasal cartilage graft and chondrocytes exhibited chondrogenic capability in vitro. Int J Med Sci. 2021;18(10): 2217–27.
15. Schaffler A, Buchler C. Concise review: adipose tissue-derived stromal cells—basic and clinical implications for novel cell-based therapies. Stem Cells. 2007;25(4): 818–27.
16. Nourian Dehkordi A, Mirahmadi Babahedyari F, Chehelgerdi M, Raesi Dehkordi S. Skin tissue engineering: wound healing based on stem-cell-based therapeutic strategies. Stem Cell Res Ther. 2019;10(1): 111.
17. Barrientos S, Brem H, Stojadinovic O, Tomic-Canic M. Clinical application of growth factors and cytokines in wound healing. Wound Repair Regen. 2014;22(5): 569–78.
18. You HH, Han SK. Cell therapy for wound healing. J Korean Med Sci. 2014;29(3): 311–19.
19. Dreifke MB, Jayasuriya AA, Jayasuriya AC. Current wound healing procedures and potential care. Mater Sci Eng C Mater Biol Appl. 2015;48:651–62.
20. Ebrahimian TG, Pouzoulet F, Squiban C, Buard V, Andre M, Cousin B, Goumelon P, Benderitter M, Castellia L, Tamarat R. Cell therapy based on adipose tissue-derived stromal cells promotes physiological and pathological wound healing. Arterioscler Thromb Vasc Biol. 2009;29(4): 503–10.
21. Jung H, Kim HH, Lee DH, Hwang YS, Yang HC, Park JC. Transforming growth factor-beta 1 in adipose derived stem cells conditioned medium is a dominant paracrine mediator determines hyaluronic acid and collagen expression profile. Cytotecnology. 2011;63(1): 57–66.
22. Tremolada C, Colombo V, Ventura C. Adipose tissue and mesenchymal stem cells: state of the art and lipogems(R) technology development. Curr Stem Cell Rep. 2016;2:304–12.
23. Vezzani B, Shaw I, Lesme H, Yong L, Khan N, Tremolada C, Colombo V, Ventura C. Adipose tissue and mesenchymal stem cells: state of the art and lipogems(R) technology development. Curr Stem Cell Rep. 2016;2:304–12.
24. Calmeyer K, Andre-Levigne D, Baquie M, Krause KH, Peppard MS, Pittet-Cuenod B, Modarressi A. Fate of systemically and locally administered adipose-derived mesenchymal stromal cells and their effect on wound healing. Stem Cells Transl Med. 2020;9(1): 131–44.
25. El Atat O, Antonios D, Hilal G, Hokayem N, Abou-Ghoch J, Hashim H, Serhal R, Hebbo C, Moussa M, Alaaeddine N. An evaluation of the stemness, paracrine, and tumorigenic characteristics of highly expanded, minimally passaged adipose-derived stem cells. PLOS ONE. 2016;11(9): e0162332.

26. Yang D, Wang W, Li L, Peng Y, Chen P, Huang H, Guo Y, Xia X, Wang Y, Wang H, Wang WE, et al. The relative contribution of paracrine effect versus direct differentiation on adipose-derived stem cell transplantation mediated cardiac repair. PLOS ONE. 2013;8(3): e59020.

27. Zhang W, Bai X, Zhao B, Li Y, Zhang Y, Li Z, Wang X, Luo L, Han F, Zhang J, Han S, et al. Cell-free therapy based on adipose tissue stem cell-derived exosomes promotes wound healing via the PI3K/Akt signaling pathway. Exp Cell Res. 2018;370(2): 333–42.

28. Zhou BR, Xu Y, Guo SL, Xu Y, Wang Y, Zhu F, Permatasari F, Wu D, Yin ZQ, Luo D. The effect of conditioned media of adipose-derived stem cells on wound healing after ablative fractional carbon dioxide laser resurfacing. Biomed Res Int. 2013;2013:519126.